Last reviewed · How we verify
TETA 4HCL (W12-60)
TETA 4HCL (W12-60) is a tetraethylammonium chloride, a potassium channel blocker.
TETA 4HCL (W12-60) is a tetraethylammonium chloride, a potassium channel blocker. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TETA 4HCL (W12-60) |
|---|---|
| Also known as | trientine tetrahydrochloride |
| Sponsor | Orphalan |
| Drug class | Potassium channel blocker |
| Target | Potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
TETA 4HCL (W12-60) works by blocking potassium channels in the heart, which can help to prolong the QT interval and prevent certain types of arrhythmias. This mechanism is thought to be beneficial in treating conditions such as atrial fibrillation for stroke prevention.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Hypokalemia
- QT interval prolongation
- Arrhythmias
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TETA 4HCL (W12-60) CI brief — competitive landscape report
- TETA 4HCL (W12-60) updates RSS · CI watch RSS
- Orphalan portfolio CI